Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma

Publisher Website
Google Scholar
Abstract
IT is generally agreed that patients with intermediate-grade and high-grade non-Hodgkin's lymphomas who have a relapse after initial therapy have a grave prognosis. Despite attempts at secondary (often called "salvage") therapy with irradiation or chemotherapy or both, few patients can be expected to be cured of their recurrent disease.Among the experimental approaches to this clinical situation is bone marrow transplantation after maximal cytoreductive chemotherapy, usually with whole-body irradiation. The use of autologous bone marrow in the procedure has obvious advantages. It also has theoretical disadvantages. The chief advantage, of course, is avoidance of the serious problems of graft-versus-host disease . . .